Table of contents


On 27 June 2016, orphan designation (EU/3/16/1687) was granted by the European Commission to Akari Therapeutics, Plc, United Kingdom, for recombinant protein derived from the saliva of the Ornithodoros moubata tick (also known as coversin or rEV576) for the treatment of Guillain-Barré syndrome.

This medicine is now known as nomacopan.

The sponsorship was transferred to Akari Malta Limited, Malta in January 2020.

Key facts

Active substance
Recombinant protein derived from the saliva of the Ornithodoros moubata tick (nomacopan)
Disease / condition
Treatment of Guillain-Barré syndrome
Date of first decision
EU designation number

Sponsor's contact details

Akari Malta Limited
Level 3 Gasan Centre
4 Zona Industrijali Triq Is Salib Ta' L Imriehel
Mriehel, Birkirkara 
BKR 3000
Tel:  +356 2065 0510

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating